Ray Therapeutics key facts
- Developer of optogenetic gene therapies designed for vision restoration purposes.
- It has raised $106.0M across 2 recorded rounds; the latest was Early Stage VC ($14.0M) in May 2023.
- Notable investors include Norwest, Novo Holdings, Deerfield Management, Platanus, 4BIO Capital — 7 tracked in total.
- Ray Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently May 2023 ($14.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Watch Ray Therapeutics: the Monday email on marks, rounds and moves
Ray Therapeutics funding rounds
2 roundsHow much has Ray Therapeutics raised?
Ray Therapeutics has raised $106 million in total; 2 of its rounds are on record. The largest on record was a $6 million early-stage round in May 2021; the most recent was a $14 million early-stage round in May 2023.
Ray Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in May 2023 ($14 million sold to 13 investors).
Ray Therapeutics investors
7 investors are on record for Ray Therapeutics, including Norwest, Novo Holdings, Deerfield Management and Platanus. The early-stage round in May 2023 drew 13 investors.
About Ray Therapeutics
Developer of optogenetic gene therapies designed for vision restoration purposes. The company utilizes bioengineered light-sensitive proteins delivered to targeted retinal cells through intravitreal injections to improve visual function, compatibility with various retinal blindness forms, enabling patients with severe retinal degeneration to regain sight, and lifelong effects from single treatments.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2021
- Employees
- 30
- Website
- raytherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ray Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.